CTKB
Cytek Biosciences Inc.
$3.86
+$0.08(+2.12%)
72
Overall
--
Value
72
Tech
--
Quality
Market Cap
$496.17M
Volume
964.66K
52W Range
$2.37 - $7.63
Target Price
$4.70
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | $128.0M | $164.0M | $193.0M | $200.5M | ||
| Total Revenue | $128.0M | $164.0M | $193.0M | $200.5M | ||
| COST OF GOODS SOLD | ||||||
| Cost of Revenue | $48.8M | $63.1M | $83.6M | $89.3M | ||
| GROSS PROFIT | ||||||
| Gross Profit | $79.1M | $101.0M | $109.4M | $111.1M | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $70.0M | $102.8M | $137.3M | $131.6M | ||
| Research & Development | $24.4M | $34.9M | $44.2M | $39.4M | ||
| Research Expense | $24.4M | $34.9M | $44.2M | $39.4M | ||
| Selling, General & Administrative | $45.5M | $67.9M | $93.1M | $92.2M | ||
| Selling & Marketing Expenses | $24.7M | $33.2M | $49.1M | $49.1M | ||
| General & Administrative Expenses | $20.8M | $34.7M | $44.0M | $43.1M | ||
| Salaries & Wages | -- | -- | $22.0M | $26.8M | ||
| Depreciation & Amortization | $900.0K | $1.7M | $2.8M | $3.5M | ||
| Depreciation & Amortization | $900.0K | -- | -- | -- | ||
| Amortization | $10.1M | $10.1M | $16.2M | $16.7M | ||
| Other Operating Expenses | $-519.0K | -- | -- | -- | ||
| OPERATING INCOME | ||||||
| Operating income | $9.2M | $-1.8M | $-27.8M | $-20.5M | ||
| EBITDA | $8.9M | $9.4M | $-4.4M | $-449.0K | ||
| NON-OPERATING ITEMS | ||||||
| Interest Expense (Non-Operating) | $1.7M | $2.6M | $2.1M | $-5.2M | ||
| Intinc | $49.0K | $4.6M | $6.4M | $5.1M | ||
| Net Non-Operating Interest Income/Expense | $-1.7M | $2.0M | $4.3M | $10.4M | ||
| Other Income/Expense | $1.5M | $1.0M | $-7.8M | $-4.6M | ||
| Other Special Charges | $-1.5M | $1.0M | $7.8M | $4.5M | ||
| SPECIAL ITEMS | ||||||
| Special Income Charges | $-1.7M | $-5.2M | $-1.6M | $-5.5M | ||
| PRE-TAX INCOME | ||||||
| EBIT | $7.7M | $3.8M | $-13.6M | $-10.9M | ||
| Pre-Tax Income | $5.9M | $1.3M | $-15.7M | $-5.7M | ||
| INCOME TAX | ||||||
| Tax Provision | $2.9M | $-1.2M | $-3.6M | $320.0K | ||
| NET INCOME | ||||||
| Net Income | $3.0M | $2.6M | $-12.1M | $-6.0M | ||
| Net Income (Continuing Operations) | $3.0M | $2.5M | $-12.1M | $-6.0M | ||
| Net Income (Discontinued Operations) | $3.0M | $2.6M | $-12.1M | $-6.0M | ||
| Net Income (Common Stockholders) | $3.0M | $2.6M | $-12.1M | $-6.0M | ||
| TOTALS | ||||||
| Total Expenses | $118.8M | $165.8M | $220.9M | $221.0M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $76.7M | $134.5M | $135.3M | $130.6M | ||
| Average Shares Outstanding (Diluted) | $81.5M | $138.6M | $135.3M | $130.6M | ||
| Shares Outstanding | $134.1M | $135.4M | $130.8M | $128.1M | ||
| Basic EPS | -- | $0.02 | $-0.09 | $-0.05 | ||
| Basic EPS (Continuing Operations) | -- | $0.02 | $-0.09 | $-0.05 | ||
| Diluted EPS | -- | $0.02 | $-0.09 | $-0.05 | ||
| Diluted EPS (Continuing Operations) | -- | $0.02 | $-0.09 | $-0.05 | ||
| OTHER METRICS | ||||||
| Accrued Preferred Stock Dividends | -- | $-2.6M | -- | -- | ||
| Commission Expenses | $-3.0M | -- | -- | -- | ||
| Marketing Expense | $1.8M | -- | -- | -- | ||
| Minority Interests | $-26.0K | $92.0K | -- | -- | ||
| Non Recurring Operation Expense | $1.7M | -- | -- | -- | ||
| Other Gand A | $20.8M | $34.7M | $44.0M | $43.1M | ||
| Other Write Off | $172.0K | -- | -- | -- | ||
| Otherunder Preferred Stock Dividend | -- | $-2.6M | -- | -- | ||
| Preferred Stock Dividends | -- | $-2.6M | -- | -- | ||
| Rent And Landing Fees | $-600.0K | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CTKB | $3.86 | +2.1% | 964.66K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |